We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Appeals Court Revives Amgen’s Sensipar Patent Challenge
The Federal Circuit Court of Appeals gave Amgen another chance to prove that Amneal’s planned generic of its hyperparathyroidism treatment Sensipar (cinacalcet) infringes on its patent.